Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 11/20 | 0.60 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS12 | P56730 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608881 | 0.90 | COMT (0.64) | COMTF10PRSS12MEN1KMT2A | |
| SCHEMBL1608458 | 0.89 | COMT (0.57) | COMTMEN1ALDH1A1KMT2A | |
| SCHEMBL1608782 | 0.87 | COMT (0.68) | COMTF10MEN1ALDH1A1KMT2A | |
| SCHEMBL30592877 | 0.87 | COMT (0.68) | COMTF10MEN1ALDH1A1KMT2A | |
| SCHEMBL1608186 | 0.82 | COMT (0.73) | COMTALDH1A1 | |
| SCHEMBL3362922 | 0.73 | COMT (0.55) | COMTMEN1KMT2A | |
| SCHEMBL3365925 | 0.72 | COMT (0.59) | COMTMEN1ALDH1A1KMT2A | |
| SCHEMBL1608934 | 0.70 | COMT (0.83) | COMTMEN1KMT2A | |
| SCHEMBL1609327 | 0.70 | COMT (0.69) | COMTALDH1A1KMT2A | |
| SCHEMBL1608786 | 0.70 | COMT (0.61) | COMTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101282957-B | New pharmaceutical compounds | ORION CORP | 2013-07-10 | — | — | CN | claimed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | claimed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | claimed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | claimed |
| CN-101282957-A | New pharmaceutical compounds | ORION CORP (FI) | 2008-10-08 | — | — | CN | claimed |
| US-12521363-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2026-01-13 | — | — | US | disclosed |
| US-20240050394-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORP (FI) | 2024-02-15 | — | — | US | disclosed |
| US-11771675-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2023-10-03 | — | — | US | disclosed |
| US-20210085635-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORPORATION (FI) | 2021-03-25 | — | — | US | disclosed |
| US-10857120-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2020-12-08 | — | — | US | disclosed |
| EP-2542220-B1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORP (FI) | 2016-11-02 | — | — | EP | disclosed |
| CN-102781424-B | Levodopa, carbidopa and entacapone are used for the treatment of Parkinsonian application | ORION CORP. (FI) | 2016-03-30 | — | — | CN | disclosed |
| CN-101282957-B | New pharmaceutical compounds | ORION CORP | 2013-07-10 | — | — | CN | disclosed |
| US-20130137729-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORPORATION (FI) | 2013-05-30 | — | — | US | disclosed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| CN-102781424-A | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | ORION CORP | 2012-11-14 | — | — | CN | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| CN-101282957-A | New pharmaceutical compounds | ORION CORP (FI) | 2008-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | COMT 1/4885F10 912/4885PRSS12 530/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | COMT 1/4885F10 210/4885PRSS12 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.